Literature DB >> 26622432

Effect of shRNA-mediated knockdown of vascular endothelial growth factor on the proliferation of choroid-retinal endothelial cells under hypoxic conditions.

Ai-Hua Liu1, Jing Sun1, Y I Shi1, Guo-Ling Sun1, Hong Zhang1.   

Abstract

The aim of the present study was to investigate the role of vascular endothelial growth factor (VEGF) in cell proliferation under hypoxic conditions. Gene knockdown of VEGF was conducted in the choroid-retinal endothelial RF/6A cell line by transfection with short hairpin RNA (shRNA), in which a shRNA fragment against VEGF was synthesized and cloned into the vector, pSilencer 2.1-U6 neo. Subsequently, a model of hypoxia was established in the RF/6A cell line via treatment with CoCl2, into which the recombinant plasmids, containing the VEGF-targeting shRNA (p-shRNA), were transfected. The study included four treatment groups, namely a control group (normal group), a hypoxia group treated with CoCl2 (CoCl2 group), a control plasmid group that were subjected to CoCl2 treatment and transfection with a pSilencer 2.1-U6 neo plasmid without the shRNA (CoCl2 + p-NC group), and a group treated with CoCl2 and transfected with a pSilencer 2.1-U6 neo plasmid containing the VEGF-targeting shRNA (CoCl2 + p-shRNA group). Subsequent to treatment, the mRNA and protein expression levels of VEGF were evaluated using quantitative polymerase chain reaction and western blot analysis, respectively, In addition, cell proliferation was assessed. RF/6A cells treated with CoCl2 reduced cell connectivity, irregular morphology and reduced thickness compared with the cells in the normal group. However, cells in the CoCl2 + p-shRNA group exhibited an improved morphology compared with the CoCl2 and CoCl2 + p-NC groups. Cell proliferation in the CoCl2 group was enhanced in a time-dependent manner. However, the hypoxia-induced increase in cell proliferation was significantly inhibited in the CoCl2 + p-shRNA group, with inhibition rates of 16, 32 and 38% at 24, 48 and 72 h, respectively. The mRNA and protein expression levels of VEGF were increased in the CoCl2 group when compared with the normal group, and these hypoxia-induced increases in VEGF expression were reduced in the CoCl2 + p-shRNA group. Therefore, the results indicated that the targeted knockdown of VEGF in vascular endothelial cells may be effective for the treatment of retinal neovascularization diseases.

Entities:  

Keywords:  CoCl2; cell proliferation; retinal neovascularization diseases; short hairpin RNA; vascular endothelial growth factor

Year:  2015        PMID: 26622432      PMCID: PMC4533154          DOI: 10.3892/etm.2015.2596

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  26 in total

1.  Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met, Rac1, HIF-1α and VEGF expression in cocultured retinal pigment epithelial cells.

Authors:  Shanshan Du; Shuai Wang; Qiang Wu; Jianyan Hu; Tingting Li
Journal:  Exp Eye Res       Date:  2013-09-06       Impact factor: 3.467

2.  Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy.

Authors:  A Cantón; R Burgos; C Hernández; C Mateo; R M Segura; J Mesa; R Simó
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

3.  Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors.

Authors:  Erwei Song; Pengcheng Zhu; Sang-Kyung Lee; Dipanjan Chowdhury; Steven Kussman; Derek M Dykxhoorn; Yi Feng; Deborah Palliser; David B Weiner; Premlata Shankar; Wayne A Marasco; Judy Lieberman
Journal:  Nat Biotechnol       Date:  2005-05-22       Impact factor: 54.908

4.  [Short hairpin RNA targeting vascular endothelial growth factor effectively inhibits expression of vascular endothelial growth factor in human retinal pigment epithelium].

Authors:  Chun-mei Cai; Bao-chen Sun; Xu-yang Liu
Journal:  Zhonghua Yan Ke Za Zhi       Date:  2006-04

Review 5.  Development and possible clinical use of antagonists for PDGF and TGF-beta.

Authors:  Carl-Henrik Heldin
Journal:  Ups J Med Sci       Date:  2004       Impact factor: 2.384

6.  Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression.

Authors:  H Ozaki; A Y Yu; N Della; K Ozaki; J D Luna; H Yamada; S F Hackett; N Okamoto; D J Zack; G L Semenza; P A Campochiaro
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-01       Impact factor: 4.799

7.  [Inhibition of VEGF expression by plasmid-based RNA interference in the retinoblastoma cells].

Authors:  Ren-Bing Jia; Xian-Qun Fan; Xiao-Li Wang; Xing-Qian Zhang; Ping Zhang; Jian Lu
Journal:  Zhonghua Yan Ke Za Zhi       Date:  2007-06

8.  Impact of alendronate and VEGF-antisense combined treatment on highly VEGF-expressing A431 cells.

Authors:  Medge Mongerard-Coulanges; Evelyne Migianu-Griffoni; Marc Lecouvey; Béatrice Jolles
Journal:  Biochem Pharmacol       Date:  2009-03-05       Impact factor: 5.858

9.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors:  Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

10.  Hypoxic regulation of vascular endothelial growth factor in retinal cells.

Authors:  L P Aiello; J M Northrup; B A Keyt; H Takagi; M A Iwamoto
Journal:  Arch Ophthalmol       Date:  1995-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.